Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics (NASDAQ: SRPT), a leader in precision genetic medicine, announced equity awards granted as material inducement for employment to 19 new hires in July 2024.
On July 31, 2024, the Compensation Committee approved these awards under the 2024 Employment Commencement Incentive Plan, aligning with Nasdaq Listing Rule 5635(c)(4).
The awards consist of an aggregate of 14,495 restricted stock units (RSUs) that will vest annually over four years, contingent on continuous employment. No stock purchase options were granted.
Sarepta Therapeutics (NASDAQ: SRPT), leader nella medicina genetica di precisione, ha annunciato l'assegnazione di premi azionari come incentivo materiale per l'assunzione di 19 nuovi dipendenti nel luglio 2024.
Il 31 luglio 2024, il Comitato per la Compensazione ha approvato questi premi ai sensi del Piano di Incentivi per l'Avvio dell'Occupazione 2024, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
I premi consistono in un totale di 14.495 unità azionarie riservate (RSU) che matureranno annualmente nel corso di quattro anni, a condizione di un impiego continuativo. Non sono state concesse opzioni di acquisto delle azioni.
Sarepta Therapeutics (NASDAQ: SRPT), líder en medicina genética de precisión, anunció la concesión de premios en acciones como incentivo material para la contratación de 19 nuevos empleados en julio de 2024.
El 31 de julio de 2024, el Comité de Compensación aprobó estos premios bajo el Plan de Incentivos por Inicio de Empleo 2024, en alineación con la Regla de Cotización Nasdaq 5635(c)(4).
Los premios consisten en un total de 14.495 unidades de acciones restringidas (RSUs) que se otorgarán anualmente durante cuatro años, dependiendo del empleo continuo. No se otorgaron opciones de compra de acciones.
세레프타 테라퓨틱스 (NASDAQ: SRPT)는 정밀 유전자 의학의 선두주자로서 2024년 7월에 19명의 신규 직원에 대해 고용 유인으로 주식 보상을 부여한다고 발표했습니다.
2024년 7월 31일, 보상위원회는 NASDAQ 상장 규칙 5635(c)(4)에 따라 2024년 고용 시작 인센티브 프로그램에 따라 이러한 보상을 승인했습니다.
이 보상은 14,495개의 제한 주식 단위(RSU)로 구성되며, 지속적인 고용 조건 하에 매년 4년에 걸쳐 베스트됩니다. 주식 매입 옵션은 부여되지 않았습니다.
Sarepta Therapeutics (NASDAQ: SRPT), un leader dans la médecine génétique de précision, a annoncé l'octroi de primes en actions comme incitation matérielle à l'embauche de 19 nouveaux employés en juillet 2024.
Le 31 juillet 2024, le Comité de Rémunération a approuvé ces primes dans le cadre du Plan d'Incentives pour le Début d'Emploi 2024, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Les primes se composent d'un total de 14.495 unités d'actions restreintes (RSU) qui seront acquises annuellement sur quatre ans, sous condition d'emploi continu. Aucune option d'achat d'actions n'a été accordée.
Sarepta Therapeutics (NASDAQ: SRPT), ein führendes Unternehmen in der Präzisionsgenetik, gab bekannt, dass im Juli 2024 Aktienvergütungen als wesentlicher Anreiz für die Beschäftigung an 19 neue Mitarbeiter gewährt wurden.
Am 31. Juli 2024 genehmigte der Vergütungsausschuss diese Vergütungen im Rahmen des 2024 Employment Commencement Incentive Plans, in Übereinstimmung mit der Nasdaq Listungsregel 5635(c)(4).
Die Vergütungen bestehen aus insgesamt 14.495 beschränkten Aktieneinheiten (RSUs), die über vier Jahre hinweg jährlich fällig werden, sofern das Beschäftigungsverhältnis fortbesteht. Es wurden keine Optionsrechte auf Aktien gewährt.
- Equity awards granted to 19 new employees, indicating growth.
- 14,495 RSUs issued, encouraging employee retention.
- No stock purchase options granted, potentially less attractive to new hires.
The employees received in the aggregate 14,495 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731742607/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
What did Sarepta Therapeutics announce on July 31, 2024?
How many restricted stock units (RSUs) were granted by Sarepta Therapeutics?
What is the vesting schedule for the RSUs granted by Sarepta Therapeutics?
Did Sarepta Therapeutics grant stock purchase options with the RSUs?
What does Nasdaq Listing Rule 5635(c)(4) relate to?
